Navigation Links
Versatile Transfection Reagent Offers Low Toxicity and Consistent,,,Performance

IH 3T3 cell lines (Figure 2).5 This study used the b-galactosidase control plasmid and varying amounts of lipid reagents for transfections.

Figure 2

The b-galactosidase activity of transfected cell lysates indicated transfection efficiency. To determine toxicity, for each volume of transfection reagent used in each cell line, we measured the concentration of cellular proteins (data not shown). LipoTAXI reagent gave the highest transfection efficiency and lowest toxicity in all three cell lines.

Transfection Efficiencies: Effect of Mycoplasma Contamination

When standardization studies are performed to determine optimized amounts of LipoTAXI transfection reagent and DNA, low efficiencies or atypical transfection profiles may be observed. This may be due to mycoplasma contaminating the cell lines, since antibiotic-resistant mycoplasma can exist in cell cultures without noticeable visual effects on cells.

Figure 3

In one laboratory, optimization of LipoTAXI reagent using the b-galactosidase reporter plasmid in HeLa cells showed uncharacteristically low efficiencies.6 Stratagenes Mycoplasma PCR Primer Set,*, which provides a quick, sensitive assay for detecting mycoplasma in cell cultures, was used to test the HeLa cells for contamination. Cell-free supernatant samples were prepared, then analyzed, according to the protocol provided with the primer set. Results indicated that mycoplasma contamination was present in the HeLa cells at the time atypical optimization profiles were observed (Figure 3, lane 2). After the contaminated cells were destroyed and the laboratory
'"/>

Source:


Page: All 1 2 3 4 5 6 7

Related biology technology :

1. A Versatile Power Supply for All Electrophoresis Applications
2. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
3. Versatile Reporter Vectors for Monitoring Viral Transduction
4. pSilencer 4.1-CMV: Versatile Vectors for Expression of siRNA, miRNA, and mRNA
5. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
6. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
7. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
8. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
9. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
10. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
11. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent

Post Your Comments:
(Date:12/2/2009)...2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.... ONCY ) announced today that in connection with it...ters have exercised in full their over-allotment o...ach unit is comprised of one common share and 0.4 ...t a price of US$3.00 per unit. Each whole common s...
(Date:12/2/2009)... Israel, December 2 Gamida Cell an...reclinical (animal study) safety and,efficacy of a...om Weill,Cornell Medical College and Gamida Cell. ...anemias such as Cooley,s Anemia. , Gamida...pand, ex vivo,populations of stem/progenitor cell...
(Date:12/2/2009)...PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NAS...iopharmaceutical company focused on endocrine ther...od and Drug Administration (FDA) has granted Fast ...ay inhibitor compound, perifosine (KRX-0401), for ...oma. Keryx Biopharmaceuticals, Inc. ("Keryx") ( KE...
(Date:12/1/2009)...ry Solomon announced that he has joined Carolina E...website at www.DrKerrySolomon.com , which was dev...s a proven LASIK, lens implant, and cataract surge...or his substantial contributions to improving visi...LASIK Surgeons, which screens LASIK surgeons based...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
...tockholders to Determine Fate of Company,s Remaini...ciNova, Inc. Offers Avigen Stockholders Extraordin...n. 9 Biotechnology Value Fund, L.P. together with...s requested that the Board of Directors of Avigen,...Meeting of the stockholders for the purpose of rep...
...all/ - Victhom Human Bionics Inc., "Victhom" (TSX:...d corporate Website at www.victhom.com . The Webs...ces in the Company,s two operating divisions; Neur...timulation device for gait disorders, and Biotroni...zed prostheses for above-knee amputees. , Commenti...
...g-Plough Corporation (NYSE: SGP ) will provide a... Koestler, Ph.D., executive vice president and pre... 27th Annual J.P. Morgan Healthcare Conference in ... 3:30 p.m. (PST) (6:30 p.m. EST). Koestler is exp... and select projects in development. , , A live a...
Other Biology Technology:Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 2Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 3Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 4Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees 5Victhom Announces Launch of Enhanced Company Website 2
(Date:12/3/2009)... Rapids, Mich. (Dec. 3, 2009) Van Andel Researc...cisely how the plant hormone abscisic acid (ABA) w... to environmental stresses such as drought and col...re , could help engineer crops that thrive in hars...food shortages. The findings could also have impl...
(Date:12/3/2009)...you ever felt overly upset by a social snubbing? Y..., Scientists have long known that opium-like pain... pain, but also some forms of emotional stress. No... member Markus Heilig shows that small genetic dif...etermine the intensity of people,s responses to so...
(Date:12/3/2009)...nish researchers have measured CO2 levels for the ...ere) over a sparsely inhabited rural area near Val... kind in the Iberian Peninsula, show that the leve... Over recent years, physicists and meteorologists ...(CO2) levels, and how these have evolved in the tr...
Breaking Biology News(10 mins):VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3CO2 levels rising in troposphere over rural areas 2Life Saving Thermal Angel Blood Warmer Is Immediately Available For Use By U S Troops In Harms Way 51758 1Life Saving Thermal Angel Blood Warmer Is Immediately Available For Use By U S Troops In Harms Way 51758 2Life Saving Thermal Angel Blood Warmer Is Immediately Available For Use By U S Troops In Harms Way 51758 3Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship 51754 1Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship 51754 2Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship 51754 3Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship 51754 4Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 1Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 2Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 3Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 4Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 5Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 6Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 7Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 8Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 9Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 10Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 11Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 12Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 13Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 14Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 15Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 16Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 17Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 18Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 19Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 20Abbott Reports Strong Second Quarter Results 3B Confirms Double Digit Earnings Growth Outlook for 2009 51750 21
...kind of learning that allows humans to get used to...uman vital signs adapt to medical interventions su... Chi-Sang Poon, a research scientist at the Harvar...HST), suggests that this innate ability to adapt, ... to design more effective and less costly artifici...
...ologie Neurovg tative (CNRS-INRA-Universit Paul C ...que (INRA-Universit Paul Czanne) and from the D ...NSERM, Hopital Purpan Toulouse), and in particular..., Directeur de Recherche CNRS, Dr Franois Terc , C...confrence and Dr Caroline Fasano, author in 2004 o...
...blishers, will publish the Journal of Coastal Cons...UCC the Coastal Union. Linking science and polic...ournals in coastal science, the International Jour... The first issue of the relaunched JCCO, with a ne... orientation and new subtitle, will be published b...
Other Biology News:Rhythmic breathing adapts to external beat through 'brain calculus' 2Rhythmic breathing adapts to external beat through 'brain calculus' 3Springer will publish Journal of Coastal Conservation 2
...0 System revolutionizes DNA sequencing, delivering...he Genome Sequencer 20 System includes: Instrume...ibrary construction, amplification, and sequencing...ly The instrument is the centerpiece of the Gen...
Cardiovascular/Renal Profile from Novascreen-a Caliper Life Sciences Company
...gle Donor • Human serum is obtained from norm...test for Human Immunodeficiency Virus Antigen (s) ...rus (Anti-HIV 1/2), Hepatitis C Virus (HCV), and N... and Non-reactive by a screening test for syphilis...
Customized Profile from Novascreen-a Caliper Life Sciences Company
Biology Products: